Opioids for Chronic Non-Cancer Pain

Table of Contents

  1. An Honest Starting Point
  2. The CDC 2022 Revision — What Changed
  3. MME: What It Means and How to Calculate It
  4. Opioid-Induced Hyperalgesia
  5. Tolerance vs Physical Dependence vs OUD
  6. Buprenorphine for Chronic Pain
  7. Methadone — Powerful and Complicated
  8. Long-Acting vs Short-Acting Opioids
  9. Risk Mitigation: PDMP, UDS, Naloxone, REMS
  10. Tapering — The VA Approach and the No-Forced-Taper Rule
  11. When Opioids ARE Appropriate
  12. Legacy Patient Management
  13. Kratom: What We Know
  14. Practical Advice for Patients
  15. Key Research Papers
  16. Research Papers
  17. Connections

An Honest Starting Point

Opioids for chronic non-cancer pain is one of the most politicized topics in medicine. In the space of a decade, the pendulum swung from aggressive prescribing (the "pain as fifth vital sign" era) to a panicked retreat in which stable, functioning patients were abruptly cut off from medications they had taken safely for years. Both extremes have harmed people. The goal of this page is neither to cheerlead for opioids nor to demonize them, but to describe how thoughtful pain physicians and the current guidelines think about them in 2026.

If you are a patient reading this, a few things to hold in mind: opioids are a real tool with real benefits for a real subset of chronic-pain conditions. They are also a real risk. The evidence base for long-term opioid therapy (more than 3 months) in chronic non-cancer pain is weaker than most people assume. But the evidence against them, at doses that worked for you for years, is not strong enough to justify tearing up a working regimen. Individualization — informed by modern guidelines, honest risk assessment, and shared decision-making — is the entire game.

The CDC 2022 Revision — What Changed

The original 2016 CDC Guideline for Prescribing Opioids for Chronic Pain was a well-intentioned document that was widely misapplied. Insurers, pharmacies, state medical boards, and even some physicians treated its suggested 90 MME/day threshold as a hard ceiling and its cautions as mandates. The result: forced tapers, abandoned legacy patients, suicides, and a measurable jump in street-fentanyl overdose deaths as cut-off patients turned to the illicit market.

In November 2022 the CDC issued a substantially revised Clinical Practice Guideline for Prescribing Opioids for Pain. The top-line changes:

Critically, the CDC guideline is guidance, not law. State laws, DEA regulations, insurer policies, and pharmacy corporate rules operate independently and often lag the science. Patients and clinicians may still encounter providers who quote the 2016 caps as if nothing changed.

MME: What It Means and How to Calculate It

MME stands for Morphine Milligram Equivalents. It is a rough attempt to compare different opioids on a single scale by converting each drug's daily dose into "how much oral morphine would that equal?" The conversion factors (as used by the CDC and most state PDMPs):

A patient on 60 mg oxycodone/day is at 90 MME. A patient on a 50 mcg/hr fentanyl patch is at roughly 120 MME. A patient on methadone 40 mg/day is at roughly 320 MME, which is why methadone is respected.

Benchmarks to keep in mind (from the revised 2022 CDC guideline, framed as points for re-evaluation, not ceilings):

Opioid-Induced Hyperalgesia

One of the strangest things long-term opioids can do is make pain worse. Opioid-induced hyperalgesia (OIH) is a paradoxical state in which opioid therapy sensitizes the central nervous system so that the patient becomes more sensitive to painful stimuli, not less. The mechanism involves NMDA receptor upregulation, descending facilitation from the rostroventral medulla, and pro-inflammatory glial activation.

Clinical clues suggesting OIH rather than tolerance:

Tolerance, by contrast, means the same dose produces less analgesia over time; increasing the dose usually restores benefit. OIH and tolerance can coexist and are often difficult to separate clinically, which is one reason a trial of careful dose reduction (or rotation to buprenorphine) is sometimes more useful than escalation.

Tolerance vs Physical Dependence vs OUD

Three terms that get tangled together in public conversation and occasionally even in clinical records. Keeping them separate matters because they have very different implications.

Tolerance is a pharmacological adaptation in which the same dose produces less effect over time. It applies to analgesia, euphoria, sedation, and respiratory depression (though not equally — tolerance to respiratory depression lags behind tolerance to analgesia, which is part of why overdose deaths can happen even in habituated users after a break).

Physical dependence is a predictable physiological state in which abrupt discontinuation produces a withdrawal syndrome: sweating, piloerection, muscle aches, yawning, lacrimation, runny nose, GI cramping, diarrhea, anxiety, restless legs. Physical dependence develops in everyone taking opioids daily for more than a few weeks. It is not addiction. It is not a moral failing. It is the expected biology of mu-opioid receptor adaptation.

Opioid Use Disorder (OUD) is the DSM-5 diagnosis for the behavioral disease of addiction. It is defined by compulsive use despite harm, loss of control, cravings, and a consistent pattern of behaviors: unauthorized dose escalation, doctor-shopping, diversion, use of non-prescribed opioids, use despite clear functional decline, and continued use despite major social, occupational, or legal consequences. The DSM-5 criteria are 11 items, and diagnosis requires 2 or more within 12 months; 2–3 is mild, 4–5 moderate, 6+ severe.

A patient who has been stable on the same opioid dose for five years, takes it as prescribed, functions well, and would go into withdrawal if it stopped is physically dependent, not addicted. Confusing the two is exactly the mistake that drove the forced-taper crisis.

Buprenorphine for Chronic Pain

Buprenorphine deserves its own section because, for chronic pain, it is one of the most underused tools in American medicine. It is a partial mu-opioid agonist with a strong binding affinity, slow receptor dissociation, and a ceiling effect on respiratory depression. In practical terms, that combination makes it measurably safer than full agonists while still providing meaningful analgesia.

Chronic-pain buprenorphine formulations approved in the U.S.:

Why buprenorphine is attractive for chronic pain:

The catch: rotation onto buprenorphine from a full agonist can precipitate withdrawal because buprenorphine kicks other opioids off the receptor but only partially activates it. Modern protocols — micro-induction (low-dose cross-titration over 7–14 days without stopping the full agonist) — have made this transition far more comfortable than the old "wait until you are in withdrawal" method.

Methadone — Powerful and Complicated

Methadone is an effective analgesic, inexpensive, long-acting, and in some ways ideal for difficult pain — particularly neuropathic pain, because it has NMDA-receptor antagonism in addition to mu-agonism. It is also among the most dangerous opioids to prescribe, and any clinician starting a patient on methadone for chronic pain should have specific experience with it.

The core problems:

When done right by an experienced prescriber, methadone can be transformative for neuropathic pain refractory to other options. When done wrong, it is a leading cause of opioid overdose death per prescription written.

Long-Acting vs Short-Acting Opioids

The 2016 CDC guideline suggested short-acting opioids for initiation of chronic therapy. The 2022 revision softened this language — the choice now depends on the clinical situation.

Short-acting (immediate-release oxycodone, hydrocodone, morphine) peak in 30–60 minutes and wear off in 3–4 hours. Pros: easier dose titration, good for episodic or breakthrough pain, lower peak-trough total opioid load than a poorly chosen long-acting. Cons: more frequent dosing, roller-coaster pharmacokinetics that can reinforce clock-watching behavior, and the "rescue" mindset.

Long-acting (oxycodone ER, morphine ER, fentanyl patch, methadone, Belbuca, Butrans) provide steadier serum levels and once- or twice-daily dosing. Pros: smoother analgesia, less peak-trough swing, less behavioral reinforcement around the clock. Cons: higher baseline opioid exposure, slower dose adjustment, and in the case of extended-release tablets a small abuse-liability from tampering (which is why many have abuse-deterrent formulations).

A common modern approach for stable chronic pain is a long-acting backbone with minimal or no short-acting rescue, rather than stacking both continuously.

Risk Mitigation: PDMP, UDS, Naloxone, REMS

These are the four practical tools that allow ongoing opioid therapy to be defensible and, more importantly, safer.

PDMP (Prescription Drug Monitoring Program). Every U.S. state operates an electronic database of controlled-substance prescriptions. Clinicians are expected (and in most states required) to check it before each opioid prescription. This is not surveillance of the patient for its own sake — it flags dangerous combinations (benzodiazepines, gabapentinoids, sleeping pills) and detects unintentional duplication from multiple prescribers after emergency visits.

UDS (Urine Drug Screening). A periodic urine test confirms that the patient is taking the prescribed opioid and is not taking unprescribed or illicit substances. Done right, it is a clinical-care tool, not a punishment mechanism. Done wrong (patients discharged for a single unexpected result without a conversation), it is one of the leading sources of therapeutic-relationship rupture in pain medicine. Current best practice: risk-stratified testing (lower frequency for stable, low-risk patients), interpretation that accounts for metabolites and cross-reactivity, and a conversation before action.

Naloxone co-prescribing. Any patient on chronic opioids — and especially anyone on ≥50 MME/day, on concurrent benzodiazepines, with sleep apnea, with a history of overdose, or with substance-use history — should be co-prescribed naloxone (Narcan nasal spray, now available over-the-counter in the U.S.) and family members trained to use it. This is standard of care in 2026. It has no downside and saves lives.

REMS (Risk Evaluation and Mitigation Strategy). The FDA's REMS program for extended-release and long-acting opioids and for transmucosal fentanyl products requires prescriber education and certain patient counseling. For fentanyl buccal tablets and similar breakthrough-cancer-pain products, enrollment is mandatory.

Tapering — The VA Approach and the No-Forced-Taper Rule

The single most important shift of the last five years is the recognition that forced tapers cause harm. Peer-reviewed data from the Veterans Health Administration, large insurance databases, and multiple states have documented that patients cut off against their will experience increased rates of overdose (often on illicit fentanyl), suicide, emergency-department visits, and dramatic worsening of pain and function.

The Veterans Health Administration, which tapered tens of thousands of patients during the 2013–2019 period, revised its own approach sharply. Current VA / Department of Defense guidance (and the CDC 2022 revision) emphasizes:

Indications where a taper is clinically justified: loss of benefit, intolerable side effects, evidence of OUD developing, serious safety events (overdose, sedation), and patient preference. "The CDC guideline says 90" is not an indication.

When Opioids ARE Appropriate

Despite the past decade's hard lessons, there is a legitimate place for opioids in chronic non-cancer pain. The clearest indications:

Opioids are a poor fit for nociplastic pain (fibromyalgia, many central-sensitization syndromes) where the problem is amplified signaling rather than tissue damage. In these conditions, opioids often provide little long-term benefit and risk making the system more sensitive over time. See central sensitization and fibromyalgia.

For peripheral neuropathy, first-line therapies remain the gabapentinoids, SNRIs (duloxetine), TCAs, and topicals; opioids are reserved for cases where those have genuinely failed. See peripheral neuropathy.

Legacy Patient Management

A "legacy patient" in opioid-medicine slang is someone who was initiated on chronic opioids (often at high doses) years or decades ago, under a different standard of care, and has been stable and functional ever since. The 2016 panic produced widespread forced tapering of these patients, with catastrophic results documented in multiple studies.

The current consensus — endorsed by the CDC 2022 revision, the AMA, the American Academy of Pain Medicine, and the FDA — is that legacy patients who are stable, functional, and not showing signs of harm should generally be maintained on their current regimen. Dose reductions should be considered only when clearly justified by a change in the patient's clinical picture, not by external pressure.

If you are a legacy patient whose prescriber is leaving practice, retiring, or refusing to continue prescribing:

Kratom: What We Know

Kratom (Mitragyna speciosa) is a tree native to Southeast Asia whose leaves contain mitragynine and 7-hydroxymitragynine, compounds with partial mu-opioid-receptor activity and some adrenergic effects. It is sold in the U.S. as a dietary supplement, without FDA approval, in powder, capsule, and extract forms.

Where the evidence stands in 2026:

Kratom is not a substitute for medical care, not a tested chronic-pain therapy, and should be disclosed to any prescriber — both because it will show up (or be missed) on certain drug screens and because it interacts with other opioids and sedatives.

Practical Advice for Patients

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on opioid prescribing, buprenorphine for pain, and safe tapering:

  1. CDC 2022 opioid prescribing guideline
  2. Buprenorphine for chronic non-cancer pain
  3. Opioid-induced hyperalgesia
  4. Forced opioid tapering and patient harm
  5. Methadone, QTc prolongation, and chronic pain
  6. Naloxone co-prescribing in chronic pain
  7. Opioid use disorder vs physical dependence
  8. Kratom and mitragynine pharmacology

Connections

Back to Table of Contents